Johnson & Johnson tops 1Q views on sales spike, but net dips


Much-higher spending and one-time charges offset a12.6 percent jump in health care giant Johnson & Johnson's first-quarter revenue, trimming its profit by 1.2 percent, but the results still beat Wall Street expectations. The maker of baby products, medical devices and blockbuster immune disorder drug Remicade on Tuesday reported revenue of $20.01 billion, topping analyst projections for $19.48 billion.



from Biotech News